Header Logo

Connection

SUZANNE FUQUA to Receptors, Estrogen

Back to Details
This is a "connection" page, showing publications SUZANNE FUQUA has written about Receptors, Estrogen.
SUZANNE FUQUA
Connection Strength
4.140
Receptors, Estrogen
  1. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010 May 15; 16(10):2702-8.
    View in: PubMed
    Score: 0.255
  2. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol. 2007; 608:130-43.
    View in: PubMed
    Score: 0.202
  3. Regulation of the estrogen receptor alpha minimal promoter by Sp1, USF-1 and ERalpha. Breast Cancer Res Treat. 2004 May; 85(2):111-20.
    View in: PubMed
    Score: 0.168
  4. Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol. 2002 Sep; 82(1):7-18.
    View in: PubMed
    Score: 0.150
  5. Estrogen receptor and breast cancer. Semin Cancer Biol. 2001 Oct; 11(5):339-52.
    View in: PubMed
    Score: 0.141
  6. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2001 Oct; 6(4):407-17.
    View in: PubMed
    Score: 0.141
  7. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9.
    View in: PubMed
    Score: 0.130
  8. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 1999 Nov 01; 59(21):5425-8.
    View in: PubMed
    Score: 0.123
  9. Estrogen receptor variants. J Mammary Gland Biol Neoplasia. 1998 Jan; 3(1):73-83.
    View in: PubMed
    Score: 0.108
  10. Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells. J Cell Biochem. 1997 Nov 01; 67(2):275-86.
    View in: PubMed
    Score: 0.107
  11. Auto-regulation of the estrogen receptor promoter. J Steroid Biochem Mol Biol. 1997 Jun; 62(2-3):155-63.
    View in: PubMed
    Score: 0.104
  12. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997 Apr 01; 57(7):1244-9.
    View in: PubMed
    Score: 0.103
  13. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
    View in: PubMed
    Score: 0.098
  14. The role of the estrogen receptor in tumor progression. J Steroid Biochem Mol Biol. 1996 Jan; 56(1-6 Spec No):87-91.
    View in: PubMed
    Score: 0.094
  15. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat. 1995 Sep; 35(3):233-41.
    View in: PubMed
    Score: 0.092
  16. Mechanisms of action of antiestrogens. Cancer Treat Rev. 1995 May; 21(3):247-71.
    View in: PubMed
    Score: 0.090
  17. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
    View in: PubMed
    Score: 0.089
  18. Estrogen receptor mutagenesis and hormone resistance. Cancer. 1994 Aug 01; 74(3 Suppl):1026-9.
    View in: PubMed
    Score: 0.086
  19. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat. 2014 Jul; 146(2):273-85.
    View in: PubMed
    Score: 0.085
  20. Hormone-nuclear receptor interactions in health and disease. The oestrogen receptor. Baillieres Clin Endocrinol Metab. 1994 Apr; 8(2):433-49.
    View in: PubMed
    Score: 0.084
  21. Prognostic factors and variant estrogen receptor RNAs in clinical breast cancer. Nucl Med Biol. 1994 Apr; 21(3):449-54.
    View in: PubMed
    Score: 0.084
  22. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55.
    View in: PubMed
    Score: 0.082
  23. Estrogen receptor variants in breast cancer. Cancer Treat Res. 1994; 71:97-109.
    View in: PubMed
    Score: 0.082
  24. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 1993 Dec 15; 53(24):5882-4.
    View in: PubMed
    Score: 0.082
  25. Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993 Feb; 51(2):135-9.
    View in: PubMed
    Score: 0.077
  26. Expression of estrogen receptor variants. J Cell Biochem Suppl. 1993; 17G:194-7.
    View in: PubMed
    Score: 0.077
  27. The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202.
    View in: PubMed
    Score: 0.077
  28. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):243-7.
    View in: PubMed
    Score: 0.075
  29. Where is the lesion in hormone-independent breast cancer? J Natl Cancer Inst. 1992 Apr 15; 84(8):554-5.
    View in: PubMed
    Score: 0.073
  30. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6.
    View in: PubMed
    Score: 0.072
  31. The importance of normal and abnormal oestrogen receptor in breast cancer. Cancer Surv. 1992; 14:31-40.
    View in: PubMed
    Score: 0.072
  32. Abnormal oestrogen receptor in clinical breast cancer. Eur J Cancer. 1992; 28(2-3):309-10.
    View in: PubMed
    Score: 0.072
  33. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991 Nov; 5(11):1571-7.
    View in: PubMed
    Score: 0.071
  34. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 01; 51(1):105-9.
    View in: PubMed
    Score: 0.067
  35. Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst. 1990 May 16; 82(10):858-61.
    View in: PubMed
    Score: 0.064
  36. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
    View in: PubMed
    Score: 0.044
  37. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.043
  38. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.042
  39. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
    View in: PubMed
    Score: 0.036
  40. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem. 2001 May 25; 276(21):18375-83.
    View in: PubMed
    Score: 0.034
  41. Production and characterization of an estrogen receptor beta subtype-specific mouse monoclonal antibody. Hybridoma. 2000 Dec; 19(6):481-7.
    View in: PubMed
    Score: 0.033
  42. Alterations in the estrogen receptor alpha mRNA in the breast tumors of African American women. J Cancer Res Clin Oncol. 2000 May; 126(5):291-7.
    View in: PubMed
    Score: 0.032
  43. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81.
    View in: PubMed
    Score: 0.031
  44. A point mutation in the human estrogen receptor gene is associated with the expression of an abnormal estrogen receptor mRNA containing a 69 novel nucleotide insertion. Breast Cancer Res Treat. 1997 Jun; 44(2):145-51.
    View in: PubMed
    Score: 0.026
  45. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.025
  46. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.024
  47. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016 06; 157(2):253-265.
    View in: PubMed
    Score: 0.024
  48. Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines. Br J Cancer. 1995 May; 71(5):974-80.
    View in: PubMed
    Score: 0.023
  49. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
    View in: PubMed
    Score: 0.019
  50. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
    View in: PubMed
    Score: 0.017
  51. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene. 2011 Sep 29; 30(39):4129-40.
    View in: PubMed
    Score: 0.017
  52. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.
    View in: PubMed
    Score: 0.017
  53. Estrogen receptor gene methylation in human breast tumors. Cancer Res. 1990 Jul 01; 50(13):3974-8.
    View in: PubMed
    Score: 0.016
  54. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol. 2009 Nov; 23(11):1815-26.
    View in: PubMed
    Score: 0.015
  55. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989 Jan 01; 49(1):145-8.
    View in: PubMed
    Score: 0.015
  56. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem. 2001 Jul 27; 276(30):27907-12.
    View in: PubMed
    Score: 0.009
  57. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997 Aug 15; 57(16):3486-93.
    View in: PubMed
    Score: 0.007
  58. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem Biophys Res Commun. 1995 May 16; 210(2):609-15.
    View in: PubMed
    Score: 0.006
  59. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol. 1993 Jun; 14(3):173-88.
    View in: PubMed
    Score: 0.005
  60. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15; 50(14):4332-7.
    View in: PubMed
    Score: 0.004
  61. Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.